An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome

BACKGROUND: Lenalidomide is an effective new agent for the treatment of patients with myelodysplastic syndrome (MDS), an acquired hematopoietic disorder characterized by ineffective blood cell production and a predisposition to the development of leukemia. Patients with an interstitial deletion of C...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebert, Benjamin L, Galili, Naomi, Tamayo, Pablo, Bosco, Jocelyn, Mak, Raymond, Pretz, Jennifer, Tanguturi, Shyam, Ladd-Acosta, Christine, Stone, Richard, Golub, Todd R, Raza, Azra
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2235894/
https://www.ncbi.nlm.nih.gov/pubmed/18271621
http://dx.doi.org/10.1371/journal.pmed.0050035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2235894/
https://www.ncbi.nlm.nih.gov/pubmed/18271621
http://dx.doi.org/10.1371/journal.pmed.0050035

Ejemplares similares